Wegovy Ireland: Price, HSE Funding News and Who Qualifies

Can you get Wegovy in Ireland, what does it cost, and will the HSE pay for it? Short answer: yes, you can get it on a private prescription. You pay the full price, roughly €235 to €355 a month at pharmacies that publish prices. The HSE does not fund it for weight loss today. That may change, because in October 2026 the state's drug cost watchdog advised the HSE to consider paying for it.

Here is where things stand on October 25, 2026, in plain English.

Wegovy Ireland news: what the NCPE said in October 2026

The National Centre for Pharmacoeconomics (NCPE) checks whether a medicine is worth the money for the HSE. In mid-October 2026 it found Wegovy (semaglutide 2.4 mg, made by Novo Nordisk) cost-effective for every patient group it looked at. It advised the HSE to consider reimbursing it, which means full or part public funding.

The catch is the total bill. The NCPE said the budget impact would be "substantial." Reports by RTÉ and The Journal give these numbers:

So the advice is a green light on value, not a yes on funding. The HSE called the recommendation "nuanced" and said budget talks with the Department of Health will run "over the coming months." If funding comes, it may start with a narrow group, such as people with the highest BMI.

Is Wegovy covered by the HSE or the medical card?

Not for weight loss, as of today. This trips up a lot of people, so here is how each scheme works for GLP-1 drugs right now:

The DPS cap of €80 a month only applies to medicines on the HSE reimbursement list. Since Wegovy is not on that list for weight loss, the cap does not help you with it.

Saxenda: the one GLP-1 the HSE pays for

Saxenda is a daily liraglutide injection. Since January 1, 2023, the HSE has reimbursed it under a managed access protocol. Your doctor applies for you one patient at a time. The protocol mainly covers adults aged 18 to 74 with a BMI of 35 or more who also have prediabetes and high heart risk. If you have not lost at least 5% of your starting weight after 12 weeks at the full 3.0 mg dose, the protocol says treatment should stop. See our Saxenda guide for how it compares to weekly drugs.

Wegovy Ireland price: what people pay per month

There is no single price. Each pharmacy sets its own, and higher doses usually cost more. A price tracker that read two Irish pharmacies' published lists on July 25, 2026 found:

Those are two pharmacies, not a full market survey, and a prescriber consultation is extra. The NCPE's own estimate of €243 a month at the 2.4 mg dose is a cost-to-the-state figure, not a shop price.

Ways to lower what you pay:

• Ask several pharmacies for their price at your exact dose. Prices move.
• Claim tax relief. Prescribed medicines usually qualify for health expenses tax relief at 20% through Revenue. Keep your receipts.
• Ask about review fees before you start. Follow-up visits add up over a year.

Buy only from a registered pharmacy with a real prescription. "Wegovy" sold without one, or as "research peptides," is not the licensed drug.

How Wegovy works and how much weight people lose

Wegovy is a weekly injection. It copies GLP-1, a gut hormone that slows the stomach and quiets hunger. The licensed dose rises every 4 weeks, from 0.25 mg to the 2.4 mg maintenance dose, so the stomach can adjust. Your prescriber sets the plan.

In the STEP 1 trial, adults without diabetes lost an average of 14.9% of their body weight over 68 weeks, versus 2.4% on placebo. In the SELECT trial, Wegovy cut the risk of heart attack, stroke or heart death by 20% in people with heart disease and overweight. That heart result is one reason the NCPE found it good value.

The most common side effects are nausea, diarrhea, vomiting and constipation, mostly while the dose is going up. Our Wegovy vs Ozempic guide explains why the two brands contain the same drug but have different uses.

The muscle problem nobody prices in

In a body scan substudy of STEP 1, lean mass made up about 39% of the weight people lost on semaglutide. If you are paying close to €3,000 or more a year, you want that money to come off as fat. Two habits matter most: eating enough protein (see our protein target guide) and lifting something heavy a few times a week (see our beginner strength program).

This is exactly what Sharpy is built for. It gives you one daily protein target, one 20-minute workout and a Shape Score that shows whether you are losing fat and keeping muscle.

Wegovy pill in Ireland

The European Commission approved the once-daily Wegovy pill (oral semaglutide 25 mg) in July 2026 for adults with a BMI of 30 or more, or 27 or more with a weight-related condition. In the OASIS 4 trial, people lost about 17% on average versus 3% on placebo. As of October 25, 2026, we could not find an Irish launch date or price. Novo Nordisk is building a tablet plant in Athlone, but that is about supply, not a local launch date.

Wegovy in Northern Ireland

Northern Ireland is part of the UK, so UK rules and prices apply there, not HSE rules. NHS access to weight loss drugs in the UK is limited by strict criteria. Our Mounjaro NHS criteria guide shows how those rules work. If you are comparing with Australia, our Ozempic Australia guide explains the PBS rules and the Wegovy PBS submission.

What to do now

1. Talk to your GP about whether Wegovy, Mounjaro or Saxenda suits you, and whether you meet the Saxenda protocol.
2. If you pay privately, compare prices and keep receipts for tax relief.
3. Watch for the HSE decision. If funding comes, early access may go to people with the highest BMI and weight-related conditions.
4. Protect your muscle from week one. Hit your protein target and train for strength.

If you are pregnant, planning a pregnancy, under 18 or have a history of an eating disorder, talk to your doctor before any weight loss medicine.

The bottom line

Wegovy in Ireland is a private-pay drug for now, at roughly €235 to €355 a month. The NCPE has said it is worth the money, but the HSE still has to decide whether the state can afford it, and that may take months. Until then, make every euro count by keeping your muscle. Sharpy tracks protein, workouts and your Shape Score in one place, so the weight you lose is the weight you meant to lose.

Sources

• RTÉ: Weight loss drug recommended to HSE for some patients (Oct 2026)
• The Journal: HSE advised to consider public funding for weight-loss jab (Oct 16, 2026)
• The Journal: State funding decision on weight loss jabs could be months away (Oct 14, 2026)
• The Irish Times: GLP-1s in Ireland, how weight-loss medications work under the HSE system (Oct 12, 2026)
• HSE Medicines Management Programme: Liraglutide (Saxenda) managed access protocol
• Healthcount: GLP-1 prices in Ireland (prices read Jul 25, 2026)
• Revenue: Health expenses tax relief
• Wilding et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM, 2021
• Lincoff et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM, 2023
• Nordic Life Science: European Commission approves Wegovy pill (Jul 2026)